# Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency

> **NCT07565155** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peter Hosein, MD** · enrollment: 40 (estimated)

## Conditions studied

- Pancreatic Adenocarcinoma
- Homologous Recombination Deficiency

## Interventions

- **DRUG:** Lorigerlimab

## Key facts

- **NCT ID:** NCT07565155
- **Lead sponsor:** Peter Hosein, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2031-06-01
- **Final completion:** 2031-06-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07565155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07565155, "Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07565155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*